Safety and Efficacy of Campath in Nonmyeloablative Transplantation
NCT00038844
Completed
Objective of the low-dose transplant regimen must produce the following effects: 1. Suppression of the patient's immune system to prevent rejection of the donor cells; 2. Control of the lymphoma. The pretransplant regimen must suppress the lymphoma sufficiently to prevent marked progression of the tumor and allow time for the GVT effect to occur.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
10/31/2011
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, Leukemia
Register for Updates
Autologous Transplantation for Chronic Myelogenous Leukemia
NCT01003054
Completed
The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML). Objectives: 1. To assess the efficacy of high dose busulfan-cyclophosphamide and autologous hematopoietic transplantation with post transplant Imatinib mesylate for the treatment of CML. The primary endpoint of the study is to determ... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
10/31/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelogenous Leukemia
Register for Updates
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
NCT00377637
Completed
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily \[bid\]) or cyclophosphamide (0.5-1.0 g/m\^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry in... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
10/31/2011
Locations: Not set, Huntsville, Alabama +107 locations
Conditions: Lupus Nephritis
Register for Updates
Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma
NCT00004006
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy followed by bone marrow transplantation in treating patients who have retinoblastoma.
Gender:
ALL
Ages:
15 years and below
Trial Updated:
10/03/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Retinoblastoma
Register for Updates
Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
NCT00427336
Completed
Primary Objectives: 1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
09/20/2011
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Aplastic Anemia
Register for Updates
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00478218
Completed
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with cyclophosphamide and dexamethasone may kill more cancer cells.\> PURPOSE: This phase II trial is studying how well giving lenalidomide together with cyclophosphamide and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2011
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +1 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00004908
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and cyclophosphamide plus peripheral stem cell transplantation in treating patients who have recurrent or refracto... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
08/25/2011
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Conditions: Lymphoma
Register for Updates
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
NCT00393029
Completed
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured in the tumor. Objectives To determine whether advanced cancers that overexpress p53 can be treated effectively with lymphocytes (white blood cells) that have been genetically engineered to contain an anti-p53 protein. Eligibility Patients 18 years of age and older w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2011
Locations: National Institutes of Health, Bethesda, Maryland
Conditions: Anti-p53 TCR-Gene
Register for Updates
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
NCT00165451
Completed
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/06/2011
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neoplasms
Register for Updates
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT00140075
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Mobile, Alabama +53 locations
Conditions: Adenocarcinoma
Register for Updates
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00609167
Completed
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide and dexamethasone together with bortezomib may kill more cancer cells. PURPOSE: This phase II trial is studying giving cyclophosphamide and dexamethasone together with b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
NCT00002630
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining peripheral stem cell transplantation with chemotherapy and radiation therapy may allow the doctor to give higher doses of radiation and chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose melphalan plus total-body irradiation and peripheral stem... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2011
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +1 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates